Insulet presents real-world clinical data on use of Omnipod system
Insulet presented real-world clinical data at the Congress of the European Association for the Study of Diabetes in Lisbon, Portugal. The data are from a study of 38,778 patients in the United States with type 1 and type 2 diabetes who received insulin using the Omnipod System with at least three months of data downloaded using Insulet Provided Glooko. The data demonstrated this use was associated with frequent fingerstick blood glucose testing through the integrated Abbott FreeStyle glucose meter and high usage of the advanced features of the Omnipod System. These findings provide meaningful insights into patient behaviors and clinical outcomes that can be used to positively impact treatment decisions. Insulet will present at its sponsored symposium at the EASD meeting on Thursday, September 14, 2017 at 7 p.m. local time.